Summary
Cardio Diagnostics reported revenue of $14,825 for the fiscal year 2025 and a net loss of $(6,498,167), or $(3.71) per share (basic and diluted, retroactively restated for a 1-for-30 reverse split). Revenue declined following the conclusion of a key testing pilot, while net loss improved versus 2024…
Source: TradingView
Exclusive AI-Powered News Insights (For Members only)
Disclaimer:This content is AI-generated from various trusted sources and is intended for informational purposes only. While we strive for accuracy, we encourage you to verify details independently. Use the contact button to share feedback on any inaccuracies—your input helps us improve!
